Akari Therapeutics to Present Trop2 ADC Data at AACR 2026
Event summary
- Akari Therapeutics' abstract accepted for poster presentation at AACR Annual Meeting 2026.
- Poster titled 'Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast' to be presented April 20, 2026.
- Akari's lead candidate AKTX-101 targets Trop2 receptor with novel PH1 spliceosome-modulating payload.
- Company aims to initiate First-In-Human trial for AKTX-101 by late 2026/early 2027.
- AKTX-102, targeting CEACAM5, also in development with same PH1 payload technology.
The big picture
Akari's presentation at AACR 2026 highlights the growing focus on RNA splicing modulation in oncology. The company's novel payload technology positions it in the competitive ADC space, where differentiation through mechanism of action is critical. Success in translating preclinical data to clinical outcomes will be key to its market positioning.
What we're watching
- Clinical Validation
- How preclinical data for AKTX-101 translates to human trials and whether the novel PH1 payload demonstrates expected efficacy.
- Competitive Positioning
- Whether Akari can differentiate its ADC technology in the crowded oncology space against established players.
- Development Timeline
- The pace at which Akari advances AKTX-101 and AKTX-102 through clinical stages and potential regulatory hurdles.
Related topics